More News of Interest

Toshiba Medical’s Premium Ultrasound Platform Enables Fast and Safe Liver Imaging

Physicians now have the powerful imaging technology they need for fast, safe and reliable evaluation of liver lesions with the premium Aplio™ i-series ultrasound platform from Toshiba Medical, a Canon Group company. With the recent expansion of LI-RADS® (Liver Imaging Reporting and Data System) to include contrast-enhanced ultrasound (CEUS)* imaging for hepatocellular carcinoma (HCC) characterization, the Aplio i-series offers an ideal solution for confident diagnoses.

Offering healthcare providers a more cost-effective, less invasive and safer solution than other radiation emitting modalities, the Aplio i-series is a highly-advanced and scalable ultrasound solution made up of the Aplio i700 and Aplio i800. Health systems, such as UC San Diego Health, are using the Aplio i-series’ imaging resolution and penetration, and comprehensive CEUS imaging and quantification package, to assess perfusion dynamics in the liver and help improve HCC surveillance results.

Quality Image/Quality Diagnosis:  Dan Skyba, director, Ultrasound Business Unit, Toshiba America Medical Systems, Inc. said, “The Aplio i-series offers the superb image quality clinicians need to make confident diagnosis and provide excellent patient care.”  He concluded, “Combining a brand new system architecture with matrix transducer technology and a world-renown CEUS imaging package, these premium systems offer best in class resolution, penetration and dynamic contrast visualization. The Aplio i-series facilitates small HCC diagnosis and surveillance, even in obese or difficult to image patients, while improving workflow and keeping patients safe and more comfortable. As the transition to a value-based healthcare system continues, the use of CEUS for characterization of focal liver lesions is an example of a cost-effective and high-value clinical solution.”

Latest Posts

Don't Miss